• In Italy, CTS assessment is based on availability of pre-existing treatments and extent of therapeutic effect scales, e.g. proof of benefi t based on strong clinical endpoints ( Table 1 and Table 2 ). Combined scores based on these two factors determine level of therapeutic innovation: important (Class A), moderate (Class B) or modest (Class C) ( Figure 1 ). 1 • In France, TC assessment comprises of actual benefi t and improvement in actual benefi t to patients compared to existing therapies, leading to assignment of a Service Médical Rendu (SMR) rating (major to insuffi cient, Table 3 • Our research highlights that a similar innovation level was allocated by the Italian CTS and the French TC to most of the eighteen medicines reviewed.
• France and Italy have complex systems for determining therapeutic innovation to set clinical value and reimbursement rates.
-Comparison between ASMR rating alone in France and Italy's classifi cation of innovative drugs is challenging due to the lack of transparency of the algorithms used for each of the new medicines in Italy. -In France, a new system of HTA appraisal is currently being suggested (Relative Therapeutic Index (RTI), new criteria proposed in 2012), which will classify new pharmaceuticals against existing comparators, based on clinical benefi t, alternative treatments, patient subgroup's interest, pharmaceutical preparation and other attributes. 8 France may benefi t from the implementation of simplifi ed and more transparent processes to assess therapeutic innovation.
• Although concepts and factors used in the assessment of innovation are similar in France and Italy, outcomes such as prices can be different.
-It is important to note that the analysis of drug prices and reimbursement levels may be misinterpreted due to possible confi dential price agreements and negotiations made between HTA agencies and pharmaceutical companies.
• Further clarifi cation of the terminology used in each set of criteria is required in both countries.
• Inconsistencies between the countries may lead to disparities in access, pricing and reimbursement of innovative medicines. • Comparative analysis of innovation and reimbursement ratings between the French and Italian systems.
INNOVATION RANKING IN FRANCE AND ITALY: DIFFERENCES AND THEIR IMPACT ON PRICING AND REIMBURSEMENT PROCESSES
• Evaluation of ex-factory price differentials between France and Italy, using Italy as a reference.
Methods
• As of May 2015, eighteen new drug entities were listed on the AIFA innovation drug list 3 , all reimbursed at 100% (Table 4) .
• In France, all eighteen drugs were evaluated based on the SMR rating except one (Sirturo ® ). Xiapex ® received an 'insuffi cient' SMR rating (Table 4 ).
• SMR rating in France was 'important' for 16/18 medicines, with 100% reimbursement for 13/16 (65% for Kalydeco ® ). Reimbursement levels for the remaining 2/16 medicines are not available (Table 4 ).
• Typically, an SMR rating of 'Important' is associated with 65% reimbursement.
However, most of the evaluated drugs are restricted for hospital / prescription use and are reimbursed at 100%.
• Nine out of 18 medicines were considered to be potential therapeutic innovations in Italy. This type of innovation categorisation is not available in the French criteria.
• Generally, drug prices in France appear to be close to or slightly lower than those in Italy (Figure 3) . 
Results

Conclusion
Major
Proof of benefi t is based on clinical endpoints or validated surrogate endpoints.
Partial
Proof of benefi t is based on clinical endpoints, validated surrogate endpoints, or uncertain results.
Minor or temporary benefi t Proof of benefi t is based on a few aspects of the disease. 
